My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.1100 +0.0400 (+57.14%)
Streaming Delayed Price Updated: 3:31 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 Next >
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via CannabisNewsWire
Topics Intellectual Property
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via ACCESSWIRE
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Supply Chain
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
KELOWNA, BC / ACCESSWIRE / July 14, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study
Via CannabisNewsWire
Topics Intellectual Property
Lexaria's Human Nicotine Study Nearing Start Date
Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH
KELOWNA, BC / ACCESSWIRE / July 7, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Signs Manufacturing and License Agreements with BevNology
KELOWNA, BC / ACCESSWIRE / June 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Grants License to AnodGen Bioceuticals
KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce a... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Grants License to Valcon Medical for the European Market
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis
Lexaria Announces 2022 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
- 25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
Via CannabisNewsWire
Lexaria Commences Multi-Week Human Clinical Hypertension Study
- HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits - This study is designed to enhance Lexaria's probabilities of success with its... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Issues Update on Human Nicotine Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
Via CannabisNewsWire
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
- Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 /... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
- Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; - DehydraTECH-CBD test articles have been delivered to the laboratory ready... 
From Lexaria Bioscience Corp.
Via AccessWire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.